Journal List > Korean J Urol > v.49(6) > 1005125

Chung, Han, Jeong, Moon, Choe, Park, Hong, Byun, and Lee: Prognostic Significance of Multifocal Tumor in Radical Prostatectomy

Abstract

Purpose

We investigate the impact of tumor multifocality on the biochemical recurrence rate after radical prostatectomy.

Materials and Methods

Data was collected from 525 patients who underwent radical prostatectomy for clinically localized prostate cancer from 2003 to 2007. We evaluated the potential associations of multifocality with various clinical and pathologic factors. The ability to predict extracapsular extension (ECE) was tested by logistic regression models, whereas biochemical recurrence (BCR) was assessed via Kaplan-Meier analyses and Cox-hazard regression models. The BCR was defined as a level of serum prostate-specific antigen (PSA) of 0.2ng/ml or greater on consecutive evaluations.

Results

Multifocality was observed to be significantly associated with the presence of a high grade Gleason pattern (p=0.014), the pT stage (p< 0.001), ECE (p=0.005) and a positive surgical margin (PSM) (p=0.019). Moreover, it was the independent predictor of ECE on multivariate logistic regression analyses (p=0.039). However, although multifocality had a significant influence on biochemical recurrence on the Kaplan-Meier analyses (log rank test, p=0.019), only the PSA level and the Gleason score were significant predictors of BCR on the multivariated Cox-hazard analyses.

Conclusions

Although multifocality was associated with adverse pathologic features, it had no significant effect on biochemical recurrence on the multivariated cox-hazard analyses.

REFERENCES

1. Smither AR, Guralnick ML, Davis NB, See WA. Quantifying the natural history of post-radical prostatectomy incontinence using objective pad test data. BMC Urol. 2007; 7:2.
crossref
2. Matthew AG, Goldman A, Trachtenberg J, Robinson J, Horsburgh S, Currie K, et al. Sexual dysfunction after radical prostatectomy: prevalence, treatments, restricted use of treatments and distress. J Urol. 2005; 174:2105–10.
crossref
3. Carter HB, Walsh PC, Landis P, Epstein JI. Expectant management of nonpalpable prostate cancer with curative intent: preliminary results. J Urol. 2002; 167:1231–4.
crossref
4. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA. 1994; 271:368–74.
crossref
5. Rakovitch E, Pignol JP, Hanna W, Narod S, Spayne J, Nofech-Mozes S, et al. Significance of multifocality in ductal carcinoma in situ: outcomes of women treated with breast-conserving therapy. J Clin Oncol. 2007; 25:5591–6.
crossref
6. Santiago RJ, Wu L, Harris E, Fox K, Schultz D, Glick J, et al. Fifteen-year results of breast-conserving surgery and definitive irradiation for stage I and II breast carcinoma: the University of Pennsylvania experience. Int J Radiat Oncol Biol Phys. 2005; 58:233–40.
crossref
7. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol. 2003; 169:517–23.
crossref
8. Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA. 1997; 277:1445–51.
crossref
9. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst. 1998; 90:766–71.
crossref
10. Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW, Scardino PT. Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol. 2002; 167:528–34.
crossref
11. Chun FK, Briganti A, Jeldres C, Gallina A, Erbersdobler A, Schlomm T, et al. Tumour volume and high grade tumour volume are the best predictors of pathologic stage and biochemical recurrence after radical prostatectomy. Eur J Cancer. 2007; 43:536–43.
crossref
12. Ates M, Teber D, Gozen AS, Tefekli A, Sugiono M, Hruza M, et al. Do tumor volume, tumor volume ratio, type of nerve sparing and surgical experience affect prostate specific antigen recurrence after laparoscopic radical prostatectomy? A matched pair analysis. J Urol. 2007; 177:1771–5.
crossref
13. McNeal JE, Price HM, Redwine EA, Freiha FS, Stamey TA. Stage A versus stage B adenocarcinoma of the prostate: morphological comparison and biological significance. J Urol. 1988; 139:61–5.
crossref
14. Villers A, McNeal JE, Freiha FS, Stamey TA. Multiple cancers in the prostate. Morphologic features of clinically recognized versus incidental tumors. Cancer. 1992; 70:2313–8.
crossref
15. Miller GJ, Cygan JM. Morphology of prostate cancer: the effects of multifocality on histological grade, tumor volume and capsule penetration. J Urol. 1994; 152:1709–13.
crossref
16. Djavan B, Susani M, Bursa B, Basharkhah A, Simak R, Marberger M. Predictability and significance of multifocal prostate cancer in the radical prostatectomy specimen. Tech Urol. 1999; 5:139–42.
17. Van Oort IM, Schout BM, Kiemeney LA, Hulsbergen CA, Witjes JA. Does the tertiary Gleason pattern influence the PSA progression-free interval after retropubic radical prostatectomy for organ-confined prostate cancer? Eur Urol. 2005; 48:572–6.
crossref
18. Pan CC, Potter SR, Partin AW, Epstein JI. The prognostic significance of tertiary Gleason patterns of higher grade in radical prostatectomy specimens: a proposal to modify the Gleason grading system. Am J Surg Pathol. 2000; 24:563–9.
19. Ruijter ET, van De Kaa CA, Schalken JA, Debruyne FM, Ruiter DJ. Histological grade heterogeneity in multifocal prostate cancer. Biological and clinical implications. J Pathol. 1996; 180:295–9.
crossref
20. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA. 1994; 271:368–74.
crossref
21. Eichelberger LE, Koch MO, Daggy JK, Ulbright TM, Eble JN, Cheng L. Predicting tumor volume in radical prostatectomy specimens from patients with prostate cancer. Am J Clin Pathol. 2003; 120:386–91.
crossref
22. Noguchi M, Stamey TA, McNeal JE, Nolley R. Prognostic factors for multifocal prostate cancer in radical prostatectomy specimens: lack of significance of secondary cancers. J Urol. 2003; 170:459–63.
crossref
23. Eggener SE, Scardino PT, Carroll PR, Zelefsky MJ, Sartor O, Hricak H, et al. Focal therapy for localized prostate cancer: a critical appraisal of rationale and modalities. J Urol. 2007; 178:2260–7.
crossref
24. Gburek BM, Kollmorgen TA, Qian J, D'Souza-Gburek SM, Lieber MM, Jenkins RB. Chromosomal anomalies in stage D1 prostate adenocarcinoma primary tumors and lymph node metastases detected by fluorescence in situ hybridization. J Urol. 1997; 157:223–7.
crossref

Fig. 1.
Kaplan-Meier analysis for biochemical recurrence.
kju-49-510f1.tif
Table 1.
Descriptive characteristics of the total patients
Variables Total Tumor type p-value
Unifocal Multifocal
No. of patients 525 141 384  
Mean age (range) 64.7±6.7 64.2±6.6 64.9±6.8 0.287
  (37-78) (43-75) (37-78)
Mean BMI 24.25±2.8 24.3±2.6 24.2±2.9 0.620
(kg/m2) (range) (17.2-34.4) (17.2-32.4) (18.0-34.4)
Mean PSA 10.8±9.1 10.8±8.7 10.8±9.6 0.994
(ng/ml) (range) (0.2-94.2) (1.0-94.2) (0.2-89.2)
Mean prostate size 40.86±14.5 42.2±15.6 40.3±14.0 0.193
(cc) (range) (14.6-114.0) (17.3-98) (14.6-114.0)

BMI: body mass index, PSA: prostate-specific antigen

Table 2.
Characteristics of the pathologic factors of the 525 men reated for radical prostatectomy
Variables Total Tumor type p-value
Unifocal Multifocal
Pathologic
 ≤T2 (%) 375 (71) 115 (82) 260 (68) <0.001
 ≥T3 (%) 150 (29) 26 (18) 124 (32)  
Gleason Score        
 ≤6 (%) 153 (29) 54 (38) 99 (26) 0.014
 7 (%) 323 (62) 73 (52) 250 (65)  
 ≥8 (%) 49 (9) 14 (10) 35 (9)  
ECE
 Negative (%) 385 (73) 116 (82) 269 (70) 0.005
 Positive (%) 140 (27) 25 (18) 115 (30)  
PSM
 Negative (%) 360 (69) 108 (77) 252 (66) 0.019
 Positive (%) 165 (31) 33 (23) 132 (34)  

ECE: extracapsular extension, PSM: positive surgical margin

Table 3.
Multivariate logistic regression models predicting ECE at the final pathology
  Odds ratio 95% CI p-value
Age 1.040 0.999-1.083 0.156
BMI 1.030 0.939-1.129 0.528
Prostate size 0.987 0.967-1.007 0.199
Multifocality 1.922 1.034-3.574 0.039
PSA 1.041 1.011-1.071 0.008
Gleason score 2.813 1.892-4.182 <0.001

ECE: extracapsular extension, BMI: body mass index, PSA: prostate-specific antigen

Table 4.
Cox proportional hazard analysis of the factors predicting biochemical recurrence after radical prostatectomy
  Hazard ratio 95% CI p-value
Age 0.982 0.927-1.039 0.522
BMI 0.992 0.855-1.151 0.915
Multifocality 2.108 0.573-7.757 0.262
PSA 1.054 1.015-1.094 0.006
Prostate volume 0.948 0.897-1.003 0.064
Gleason score 2.114 1.296-3.448 0.003
PSM 1.870 0.651-5.373 0.245
ECE 0.838 0.286-2.455 0.747

CI: confidence interval, BMI: body mass index, PSA: prostate-specific antigen, PSM: positive surgical margin, ECE: extracapsular extension

TOOLS
Similar articles